Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Tenny Mudianto(New York University), Ravindra Uppaluri(Brigham and Women's Hospital), Erica K. Barnell(Washington University in St. Louis), Ann Marie Egloff(Brigham and Women's Hospital), Malachi Griffith(Washington University in St. Louis), Zachary L. Skidmore(James S. McDonnell Foundation), Katie M. Campbell(University of California, Los Angeles), Jason A. Webb(Duke University), Tusar Giri(Washington University in St. Louis), Douglas R. Adkins, Gavin P. Dunn(Massachusetts General Hospital), Ibrahim Ozgenc(Dana-Farber Cancer Institute), Obi L. Griffith(Washington University in St. Louis), Paul Zolkind(Washington University in St. Louis), Rachel Riley(University of Delaware)
Cited by 40
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795